Dexanabinol
Alternative Names: Dexanabinone; ETS-2101; HU-211; PA-50211; PRS-211007; SinnabidolLatest Information Update: 07 Oct 2025
At a glance
- Originator Hebrew University of Jerusalem
- Developer Northern Institute for Cancer Research; Pharmos Corporation; Tangram Therapeutics; University of California, San Diego
- Class 3-ring heterocyclic compounds; Antineoplastics; Cannabinoids; Neuroprotectants; Small molecules
- Mechanism of Action Apoptosis stimulants; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain cancer; Malignant melanoma; Solid tumours
- Discontinued Brain injuries; Glaucoma; Mild cognitive impairment; Multiple sclerosis
Most Recent Events
- 01 Oct 2025 e-Therapeutics is now called Tangram Therapeutics
- 28 May 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Late-stage disease) in Germany (IV, Infusion)
- 28 May 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Late-stage disease) in Poland (IV, Infusion)